anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pathogenic variants of polycomb repressive complex-2 (PRC2) subunits are associated with overgrowth syndromes and neurological diseases. EZH2 is a major component of PRC2 and mediates the methylation of H3K27 trimethylation (H3K27me3). Germline variants of EZH2 have been identified as a cause of Weaver syndrome (WS), an overgrowth/intellectual disability (OGID) syndrome characterized by overgrowth, macrocephaly, accelerated bone age, intellectual disability (ID), and characteristic facial features. Germline variants of SUZ12 and EED, other components of PRC2, have also been reported in the WS or Weaver-like syndrome. EZH1 is a homolog of EZH2 that interchangeably associates with SUZ12 and EED. Recently, pathogenic variants of EZH1 have been reported in individuals with dominant and recessive neurodevelopmental disorders. We herein present sisters with biallelic loss-of-function variants of EZH1. They showed developmental delay, ID, and central precocious puberty, but not the features of WS or other OGID syndromes.
BACKGROUND: This paper describes the design and protocol of a pragmatic, randomized trial to evaluate the comparative effectiveness of shared decision making versus motivational interviewing plus cognitive behavioral therapy for chronic pain for the voluntary tapering of opioid dose in adults with chronic noncancer pain. Integrated Services for Pain: Interventions to Reduce Pain Effectively (INSPIRE) is a multicenter, randomized trial conducted at three academic health centers in the southeastern United States. Participants are adults receiving long-term opioid therapy of at least 20 morphine milligram equivalents daily for chronic noncancer pain.
METHODS: Participants were randomized to either the shared decision-making intervention or the motivational interviewing session and cognitive behavioral therapy for chronic pain intervention. All participants also received guideline-concordant care supporting opioid pharmacotherapy. The primary outcome was change from baseline in average daily prescribed opioid dose at 12 months, using prescribing data from electronic health records. Secondary outcomes were Patient-Reported Outcomes Measurement Information System Pain Interference and Physical Function at 12 months.
CONCLUSION: This trial evaluates the comparative effectiveness of shared decision making versus motivational interviewing plus cognitive behavioral therapy for chronic pain for the voluntary tapering of opioid dose in adults with chronic noncancer pain. Results from this study can guide clinicians, researchers, and policymakers as they seek to reduce opioid prescribing and improve management of chronic pain.
CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov Identifier: NCT03454555 (https://clinicaltrials.gov/ct2/show/record/NCT03454555). Participant enrollment began on June 26, 2019.
PURPOSE:To preserve a medicated bath by preventing the generation of a putrid smell and slime by the sterilizing and bactericidal action of an eluted Ag<+> ion by immersing water-soluble glass containing monovalent Ag in its composition in the medicated bath as a water treatment agent. CONSTITUTION:A water treatment agent composed of water-soluble glass containing monovalent Ag in its composition is immersed in a medicated bath (e.g. hot bath water having a natural herb, a herb for a herb medicine, citrus fruits and a synthetic bathing agent dissolved therein) and an Ag<+> ion is eluted from said glass to treat and preserve the medicated bath. The water-soluble glass is prepared by containing, for example, Ag2O in a composition containing mesh forming oxide composed of one or more kind of SiO2, B2O3 and P2O5, mesh modifying oxide composed of one or more kind of Na2O, K2O or CaO and intermediate oxide such as Al2O3 or TiO2 as monovalent Ag. A pref. composition consists of SiO2 15-80, B2O3 30-70, Na2O 7-20 and Ag2O 0.1-2.5 on a basis of pts.wt. In use, said composition is immersed as it is or wrapped in water permeable cloth.
During an earlier phase 2 base trial (study # NCT00074997), HIV-1 infected patients received a gene therapy product (anti-HIV-1 Ribozyme \[OZ1\]). Gene therapy is an investigational treatment where genes are inserted into an individual's cells and tissues to treat a disease. The gene therapy OZ1 is thought to have anti-HIV-1 actions. This is an Observational Study to provide long term follow-up of those HIV-1 infected patients who received the gene therapy product (anti-HIV-1 Ribozyme \[OZ1\]) as part of the earlier study. Patients are seen twice yearly until 5 years from initial infusion of study drug has elapsed and then yearly until withdrawal or study completion. The study will monitor for and record any ill effects from the gene therapy product to provide long term safety information. Observational study - no investigational drug administered.
PROBLEM TO BE SOLVED: To obtain a preparation for external use such as for a cosmetic material, capable of effectively suppressing various disorders caused by singlet oxygen in living bodies, e.g. immediate melanism generated by the oxidation of DOPA by allowing to contain a compound having a specific reaction rate constant with a singlet oxygen as an effective component. SOLUTION: This preparation for external use contains a compound having >=1×10<6> M<-1> s<-1> reaction rate constant with a singlet oxygen as an effective component and preferably a UV absorber (e.g. 4-t-butyl-4'- methoxydibenzoylmethane, etc.). To screen the compound, e.g. is to irradiate laser of a UV ray wave length to a system in which generation of the singlet oxygen is known, measure a minute emission in the near infrared region which is specific to the singlet oxygen, then measure the emission when a compound to be tested is added to the same system and calculate the constant from the reduction of the emission in the near infrared region and, as a concrete example, β-carotene can be used for this purpose.
Hepatocellular carcinoma (HCC) is one of the leading causes of death from cancer worldwide, developing on cirrhosis in 90% of cases. The prognosis of patients with HCC remains poor with an overall survival of around 10% at 5 years for all tumor stages combined. The diagnosis of HCC relies on non-invasive conventional imaging criteria (computed tomography \[CT\] and/or magnetic resonance imaging \[MRI\]) and/or histology. Conventional imaging (liver CT and/or MRI and lung CT) enables HCC staging according to the Barcelona Clinical Liver Cancer (BCLC) system, linking each stage to therapeutic modalities. Accurate staging with reliable imaging methods is therefore crucial to determine the best treatment strategy. The principal objective is to demonstrate that the identification of new tumor lesions by an experimental procedure combining 18F-FDG and 18F-Fluorocholine PET-CT scans in patients with HCC, modifies the initially planned therapeutic strategy of a curative treatment palliative treatment, from locoregional palliative treatment to systemic palliative treatment.
Patients with nodal metastases undergo salvage oligometastasectomy. Following recovery, patients undergo SBRT or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion. Within 4 months following completion of salvage therapy (defined as the combination of oligometastasectomy and/or bone radiation) and depending on PSA response as well as previous treatment, patients may receive adjuvant nodal IMRT.
Administration: Decitabine is reconstituted with 5 ml sterile water to facilitate subcutaneous administration. Decitaboine is given by subcutaneous injection. Venetoclax is taken as a tablet prepared by patients pharmacy. Venetoclax is given at a dose of 400 mg po once per week concurrently with the Decitabine dose (+/- 1 day allowed ).
This invention details a method for introducing a central nervous system (CNS) stimulant into the human circulatory system to aid in the waking process of the human sleep cycle. An orally administrable pharmaceutical containing an outer layer of delayed release coating encapsulates an inner core of active substance. The outer layer is designed to maintain its integrity for a period of 4 to 10 hours. For an eight hour sleep period the unit is taken 8 hours prior to the time the individual wishes to wake up. During the sleeping period the outer layer degrades in the digestive system and exposes the active substance. The active substance is then absorbed, in a single dose, and carried into the circulatory system. The active substance provides a stimulating effect to the central nervous system which provides beneficial effects in the waking process.
A system and method for rapidly identifying suspected persons using AI interrogation communication; the method comprises the following steps: intelligent terminal, service platform, computer terminal. The intelligent terminal is provided with inquiry software, an inquiry scheme is selected according to the morning, noon and evening characteristics of infectious diseases, registration information, peripheral information and user characteristics, and AI is used for participating in intelligent inquiry with the user. Comparing the content answered by the user with the characteristics of the infectious diseases in the morning, the evening and the evening, and intelligently identifying whether the user belongs to suspected personnel, suspected level and disease degree; the inquiry conclusion is displayed in the intelligent terminal of the user; and uploading the inquiry conclusion to a service platform, and taking corresponding treatment isolation measures by the epidemic prevention personnel to verify the disease patient. The staff operates the computer terminal to control various functions of the service platform. The invention has the function of self-modification and perfection and is suitable for various epidemic situations. The system is built at ordinary times, suspected people are quickly identified when the epidemic situation is outbreak, and the epidemic situation is efficiently prevented from spreading. The invention has a huge market.
Patients of the intended target group (e.g. MUST score ≥ 1, with or at risk of disease related malnutrition) with an anticipated period of nutritional support ≥ 4 weeks will be changed / started on an equivalent prescription of 'AYMES ActaGain' for a period of 30 days.
An agent for changing the color of keratinic materials, such as human hair and/or skin, comprising; (a) at least one aliphatic or aromatic alcohol having about 2 to about 8 carbon atoms, (b) at least one clay mineral modified with quaternary ammonium compounds, and (c) at least one colour pigment. The agent may be a hair mascara. Preferably, the alcohol is ethanol, present in at least about 30 wt.%. Preferably, the composition has a water content of between 0 and 3 wt.%. Most preferably, the clay mineral is one of montmorillonite and sepiolite. Most preferably, the hydrophobically modified clay material comprises a first clay (sepiolite), a second clay (montmorillonite) and a third clay (hectorite). Preferably, the agent further comprises an oil component, e.g. isopropyl myristate. Also claimed in a method of using the agent and the use of such an agent for changing the color of keratinic materials.
1,228,615. Benzofuran carboxylic acids. J. R. GEIGY A.G. 26 July, 1968 [28 July, 1967], No. 35699/68. Heading C2C. Novel compounds of the general Formula (I) wherein Q represents a chlorine or bromine atom, R represents hydrogen or C 1-4 alkyl group, Y represents hydrogen or the methyl group and Z 1 as well as Z 2 independently represent hydrogen, a C 1-4 alkyl group or alkoxy group or a fluorine chlorine or bromine atom, as well as their salts with inorganic or organic bases are obtained (a) by reacting according to Friedel-Crafts, a compound of the general Formula III with a carboxylic acid chloride of the general Formula IX or (b) by adding halogen to a compound of the general Formula II and, if desired, converting the reaction product into a salt with an inorganic or organic base. Therapeutic preparations containing the compounds of Formula I and having diuretic and saluretic activity are administered orally.
[GB1228615A]
The potential of non-invasive Transcranial Magnetic Stimulation (TMS) as a therapeutic tool for improving schizophrenic symptoms, in particular resistant hallucinations, has been increasingly studied over the past decades. Several studies have demonstrated that low-frequency patterns of repetitive TMS (rTMS) on the left temporoparietal junction (TPJ), which are known to decrease local activity, significantly reduce auditory verbal hallucinations in schizophrenic patients. In spite of highly promising results, a high level of inter-individual variability in the response to non-invasive brain stimulation treatments, and the fact that rTMS may prove ineffective in some patients, keep spurring controversy on the efficacy of these approaches as currently performed, and on how to increase its efficacy and consistency. To date, few studies have aimed to explain this variability when, in fact, a better understanding of this common phenomena in the neurostimulation domain would clearly increase the effectiveness of this treatment, and lead to individualized therapeutic approaches specifically tailored to the conditions of each patient. Moreover, many questions stand, particularly regarding the influence of rTMS treatment on the anatomical and functional connectivity in schizophrenic patients.

Accordingly, the objectives of this project are to better understand the impact of rTMS on the brains of patients with resistant auditory hallucinations, and to use this information not only to better understand this condition but to develop more efficient and consistent therapies. The investigators hypothesize that there is a baseline difference in anatomical and/or functional connectivity between responder and non-responder patients who are treated with rTMS. Therefore, this project aims to determine some anatomical and functional connectivity markers of response to rTMS treatment in patients with schizophrenia. For this, the investigators compare the patterns of diffusion tensor imaging (DTI) white matter tractography and resting-state functional magnetic resonance imaging (fMRI) data between responder and non-responder patients to rTMS treatment. Moreover, the investigators believe that rTMS can increase the functional connectivity between frontal and temporo-parietal cortices in schizophrenic patients associated with improvements in auditory hallucinations. Therefore, the second objectives of this work are to evaluate the impact of rTMS in functional connectivity in patients with schizophrenia by comparing the DTI and resting-state fMRI data before and after rTMS treatment in both responder and non-responder patients.
Risk Summary 

Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breast-feeding females. This reduction can occur at any time but is less likely to occur once breast-feeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breast-feeding. (see DOSAGE AND ADMINISTRATION). The developmental and health benefits of breast-feeding should be considered along with the mother’s clinical need for Portia and any potential adverse effects on the breast-fed child from Portia or from the underlying maternal condition.
Spinal cord injury is a serious type of central nervous system injury that not only causes movement disorders, but also damages the bladder, intestines, and autonomic nervous circuits related to sexual function, leading to urinary and defecation disorders. Sacral nerve modulation is a technology that applies low-frequency electric pulse to specific sacral nerve continuously to affect and regulate the function of target organs, so as to treat urgent urinary incontinence, overactivity of bladder, urinary retention, fecal incontinence and other diseases. However, there is currently no consensus on whether this technology can treat urinary and defecation dysfunction caused by spinal cord injury, and its specific mechanism still needs to be studied. Existing research shows that this technique can reduce the excitability of sphincter by inhibiting the protective reflex to treat urinary retention; Treating detrusor overactivity by inhibiting detrusor muscle activity without affecting urethral resistance and detrusor muscle contraction during urination. This study hypothesizes that sacral nerve modulation intervention after spinal cord injury can reduce bladder spasms, maintain bladder compliance, bladder capacity, and low bladder filling pressure, delay the progression of bladder fibrosis and hydronephrosis after spinal cord injury, and improve symptoms such as constipation. Based on the above evidence and hypotheses, we designed a single arm clinical trial to evaluate the effectiveness and safety of sacral nerve modulation surgery in treating urinary and defecation dysfunction after incomplete spinal cord injury, especially in preventing complications such as bladder fibrosis and hydronephrosis. We also evaluated the impact of sacral nerve modulation surgery on the quality of life of patients after spinal cord injury, as well as the improvement effect of sacral nerve modulation surgery on urinary and reproductive system related symptoms and intestinal symptoms.
Arrhythmias such as atrial fibrillation, ventricular tachycardia, and sudden death remain major causes of morbidity and mortality. Their prevalence increases in our ageing populations. Modern therapy of these conditions, using a combination of drugs, devices, and interventions, can reduce the disease burden associated with cardiac arrhythmias. This prospective cohort study will collect detailed clinical, procedural, and outcome information in a large cohort of patients with arrhythmias seen in a tertiary care center. Clinical phenotyping will be enhanced by biosampling and analysis of circulating biomolecules. Digital capture of clinical information and of follow-up data is planned.
Each subject will receive a single administration during each of the 5 treatment periods as follows: 40 and 60 mg in the fed and fasted state, and 20 mg in the fed state. Subjects will be randomized to one of four dosing sequences.
Subjects will undergo MRI for quantitative (2D and 3D) evaluation of plexiform neurofibroma size, MR perfusion scan, and fludeoxyglucose (18FDG) PET scan at the time of study entry. Subjects who are treated for plexiform neurofibroma will undergo another 18FDG PET scan after one year of study entry.
Baseline measurement will be done in the rehabilitation center. Prescription for rehabilitation will be determined based on the result of baseline measurement. Participants will receive rehabilitation intervention that include telerehabilitation (video conference regular meeting, text message reminder, and mobile app). Participants will attend a regular check up at the center once a month. After 12 weeks post intervention measurement will be taken.
Tooth wear is multi-factorial presenting as a combination of abrasion, attrition, and erosion. This case report represents a case of combined tooth wear in a 46-year-old Indo-Trinidadian male, with a predominant erosive component with both the clinical signs and features of intrinsic and extrinsic erosion. This patient case is unique since the wear predominated by dental erosion has occurred rapidly evidenced by the physical clinical appearance of a lack of compensation and the upper left premolars and molars relatively unaffected by the overall effects of tooth wear. This lack of compensation, where opposing teeth have not supra-erupted to maintain inter-arch stability, and the maintenance of occlusal vertical dimension on the left due to the non-worn posterior maxillary teeth, provides the benefit of simplifying subsequent restorative management. The medical and diet history corroborates the diagnoses of intrinsic and extrinsic erosion respectively. Complications noted with rapid tooth wear, such as dentine sensitivity and pulpal necrosis are known sequelae of tooth wear however the patient presented in this case report shows a concomitant high caries experience and poor oral hygiene. Cases such as the one presented here require not only comprehensive dental management, utilizing a restorative approach but also medical referral for confirmation of a diagnosis and management of gastroesophageal reflux disease. Inherent to the management of this patient should be a multidisciplinary medical and dental approach, with confirmation and management of the cause of the intrinsic erosion as well as restorative dental management, together with dietary counseling to mitigate the effect of intrinsic and extrinsic sources of acid on dental hard tissue. A key lesson learned from this case is the importance of history and targeted questioning when trying to determine the cause of tooth wear dominated by intrinsic and extrinsic erosion.
A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
Subjects in this arm will receive vitamin B12 supplement (injectable)along with their routine antidepressant treatment as prescribed by their primary physicians. subjects will be blind to their arm allocation and will receive injections in a concealed manner with injection vials covered with foil.
The study is designed to examine histologic wound healing following ridge preservation using cancellous bone allograft that has been prepared either by freeze-drying (FDBA) or by a solvent-based processing method (PUROS). This entire protocol involves procedures that are standard care. All materials are FDA-approved materials being used in an FDA-approved manner. The test group subjects will have extraction sockets grafted with a cancellous non-freeze-dried bone allograft (called PUROS graft). This test group will be compared to an active control group using cancellous freeze-dried bone allograft (called FDBA). The null hypothesis is that there will be no significant difference in formation of new vital bone between treatment groups (primary outcome).

Each subject will provide a single non-molar tooth site for study treatment. After tooth extraction, the graft material will be placed and covered by a resorbable collagen membrane. Following 3 months of healing, the dental implant will be place, at which time a core of bone will be removed from the site as part of the preparation for the implant. The core biopsy will then be evaluated for the primary histologic outcome of % vital bone formation and secondary histologic outcome of % residual graft material.
PURPOSE:A nonpoisonous dyeing agent composition useful as hair dyeing agent, fiber dyeing agent, etc., containing a dyestuff raw material having the same structure of as that of natural melanine, obtained by blending an O- dihydroxybenzene compound with a catalyst consisting of a specific metal complex. CONSTITUTION:An O-dihydroxybenzene compound (e.g., catechol, O-dihydroxy phenylalanine, etc.) or its derivative is blended with a metal complex consisting of a metal (e.g., copper, iron, Mn, Co, etc.), an a low-molecular ligand containing an imidazole ring, pyridine ring, or porphyrin ring, or a high polymer ligand of a polymer of a compound containing the ring, or a polyethyleneimine, to give a dyeing agent composition. The composition is applied to the hair of fibers, and can form a nonpoisonous dyestuff similar to melanine dyestuff on-site. It has higher reaction rate and reaction yield than an existing dyestuff formation reaction. Addition of an oxidizing agent promotes the reaction more.